Skip to main content
EVMN logo

EVMN · Evommune, Inc. · Investor Relations

Track EVMN — free
$7.04 -0.20 (-2.76%) At close · Nov 20
Market Cap
$291.10M
Shares
41.35M
Volume · Nov 20 549.4K Avg daily vol (3M) 834K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-02 15:25 UTC 9th Annual Evercore Healthcare Conference Conference

Recent news

Date Headline
2026-11-12 Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
2026-11-09 Evommune to Present at Upcoming Investor Conferences
2026-11-05 Evommune to Host Webcast on EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
2026-11-05 Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
2026-11-04 Evommune Announces $30 Million Private Placement
2026-11-04 Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
2026-10-01 Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
2026-09-23 Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
2026-09-09 Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
2026-08-06 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-07-30 Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
2026-06-29 Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
2026-05-07 Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
2026-03-05 Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
2026-02-13 Evommune Announces $125 Million Private Placement
2026-02-10 Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
2025-12-11 Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Past events

Date Event Type
2026-11-18 2026 Jefferies Global Healthcare Conference Conference
2026-11-11 Stifel Healthcare Conference 2026 Conference
2026-11-11 Stifel 2026 Healthcare Conference Fireside Chat Conference
2026-11-05 EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader Event
2026-10-01 Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress Presentation
2026-06-02 2026 Annual Meeting of Stockholders Shareholder meeting
2026-04-13 KOL Webinar Highlighting Role of MRGPRX2 in Migraine Event
2026-02-10 Evommune EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis Event

Source: https://ir.evommune.com/

Key facts CIK 2044725 CUSIP 30054Y107 13F (30d) 99 filings 97 filers Visit website Investor relations